The T cells in meningioma showed five additional drug-target kinases that were significantly increased in expression compared to VS (CSF1R, LYN, ABL, MAP2K1, and BRAF), whereas VS had only one drug-target kinase, KDR (Fig. 5A). Here, MAP2K1 is linked to meningioma.